Evidence map›Paper›PMID 39383457›Full record

ArticleBlood advances2025

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.

Zachary M Avigan, Saoirse Bodnar, Darren Pan, Jerrel Catlett, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Shambavi Richard, Sundar Jagannath and 3 more

Abstract read
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zachary M AviganDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-1208-9260
Saoirse BodnarDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Darren PanDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Jerrel CatlettDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Joshua RichterDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-0274-0585
Larysa J SanchezDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Cesar RodriguezDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Adriana C RossiDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Shambavi RichardDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Sundar JagannathDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-2934-6518
Hearn Jay ChoDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-4481-5757
Samir ParekhDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Santiago ThibaudDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0001-8454-5136

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
Institutional Career Development CoreKL2TR004421 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Inga Peter · 2022 to 2026
$6.2M
Development of a multi-omic clinical decision platform to guide personalized therapyR01CA244899 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAREKH, SAMIR · 2020 to 2024
$2.8M
Targeting SOX11 in Mantle Cell LymphomaR01CA252222 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAREKH, SAMIR, WANG, MICHAEL · 2020 to 2024
$2.8M
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA270375 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nina Bhardwaj, JAMES L. M. FERRARA · 2022 to 2026
$2.5M
NCATS NIH HHS KL2 TR004421NCI NIH HHS K12 CA270375NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA244899NCI NIH HHS R01 CA252222
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39383457
PMCPMC11758837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.